From progression to progress: The future of multiple sclerosis.

Multiple sclerosis digital biomarker disease progression fluid biomarker pathophysiology

Journal

Journal of central nervous system disease
ISSN: 1179-5735
Titre abrégé: J Cent Nerv Syst Dis
Pays: United States
ID NLM: 101595026

Informations de publication

Date de publication:
2024
Historique:
received: 03 11 2023
accepted: 08 04 2024
medline: 7 5 2024
pubmed: 7 5 2024
entrez: 7 5 2024
Statut: epublish

Résumé

Significant advances have been made in the diagnosis and treatment of multiple sclerosis in recent years yet challenges remain. The current classification of MS phenotypes according to disease activity and progression, for example, does not adequately reflect the underlying pathophysiological mechanisms that may be acting in an individual with MS at different time points. Thus, there is a need for clinicians to transition to a management approach based on the underlying pathophysiological mechanisms that drive disability in MS. A Canadian expert panel convened in January 2023 to discuss priorities for clinical discovery and scientific exploration that would help advance the field. Five key areas of focus included: identifying a mechanism-based disease classification system; developing biomarkers (imaging, fluid, digital) to identify pathologic processes; implementing a data-driven approach to integrate genetic/environmental risk factors, clinical findings, imaging and biomarker data, and patient-reported outcomes to better characterize the many factors associated with disability progression; utilizing precision-based treatment strategies to target different disease processes; and potentially preventing disease through Epstein-Barr virus (EBV) vaccination, counselling about environmental risk factors (e.g. obesity, exercise, vitamin D/sun exposure, smoking) and other measures. Many of the tools needed to meet these needs are currently available. Further work is required to validate emerging biomarkers and tailor treatment strategies to the needs of individual patients. The hope is that a more complete view of the individual's pathobiology will enable clinicians to usher in an era of truly personalized medicine, in which more informed treatment decisions throughout the disease course achieve better long-term outcomes.

Identifiants

pubmed: 38711957
doi: 10.1177/11795735241249693
pii: 10.1177_11795735241249693
pmc: PMC11072059
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11795735241249693

Informations de copyright

© The Author(s) 2024.

Déclaration de conflit d'intérêts

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Jiwon Oh (J)

St. Michael's Hospital, Toronto, ON, Canada.

Paul S Giacomini (PS)

Montreal Neurological Institute and Hospital, Montreal, QC, Canada.

V Wee Yong (VW)

University of Calgary and Hotchkiss Brain Institute, Calgary, Canada.

Fiona Costello (F)

University of Calgary and Hotchkiss Brain Institute, Calgary, Canada.

François Blanchette (F)

Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.

Mark S Freedman (MS)

Department of Medicine¸ University of Ottawa, Ottawa, ON, Canada.
The Ottawa Hospital Research Institute, Ottawa, QC, Canada.

Classifications MeSH